Competition gets fierce for innovative science

From FierceBiotech

At the height of recession, biotechs were hurting for cash. Big Pharma and its deep pockets were there to cherry-pick the best science at an affordable price from small companies that had little choice but to make deals. But the balance of power has shifted in the past year. Pharma is now face-to-face with the patent cliff, and hardly a week goes by without mention of the industry’s unproductive, yet very costly, R&D spending. The industry is scrambling for innovative pipeline programs–and biotechs are in the position to gain from Big Pharma’s pipeline troubles. Read more…